Related Experiment Videos
Monotherapy is appropriate for nosocomial pneumonia in the intensive care unit
1Department of Medicine, New England Medical Center, Boston, MA 02111.
Abstract:
The antibiotic therapy of pneumonia in the patient receiving intensive care has traditionally required the use of two agents, usually a beta-lactam or other broad spectrum agent and an aminoglycoside. A large body of data is now available indicating that initial empiric therapy with a broad spectrum agent (third-generation cephalosporin, carbapenem or fluoroquinolone) is as efficacious as combination therapy in the treatment of critically ill patients with pneumonia. If Pseudomonas aeruginosa is isolated, a second antibiotic may need to be added. Overall, approximately 60% of patients can be successfully treated with any of these regimens. The historic reasons that established antibiotic combinations as the standard for therapy are critically examined and put into perspective. Studies of pharmacokinetics, experimental pneumonia and clinical trials completed in the last decade show that for most cases of nosocomial pneumonia, monotherapy is an acceptable regimen.
Insights
For critically ill pneumonia patients, single-agent antibiotic therapy is as effective as combination therapy. Monotherapy is acceptable for most cases of hospital-acquired pneumonia, simplifying treatment protocols.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Traditionally, pneumonia in intensive care units (ICUs) required dual antibiotic therapy, often a beta-lactam plus an aminoglycoside.
- This combination approach was historically established as the standard of care for critically ill patients.
Purpose of the Study:
- To evaluate the efficacy of monotherapy versus combination antibiotic therapy for hospital-acquired pneumonia in critically ill patients.
- To critically examine the historical basis for combination antibiotic therapy and its current relevance.
Main Methods:
- Review of pharmacokinetic studies, experimental pneumonia models, and clinical trials from the past decade.
- Analysis of data comparing broad-spectrum monotherapy (third-generation cephalosporin, carbapenem, or fluoroquinolone) with combination therapy.
Main Results:
- Initial empiric broad-spectrum monotherapy demonstrates comparable efficacy to combination therapy for pneumonia in critically ill patients.
- Approximately 60% of patients achieve successful treatment outcomes with either monotherapy or combination regimens.
- A second antibiotic may be necessary only if Pseudomonas aeruginosa is identified.
Conclusions:
- For most cases of nosocomial pneumonia, monotherapy is an acceptable and effective treatment regimen.
- The traditional reliance on dual antibiotic therapy for ICU pneumonia is being re-evaluated based on current evidence.
- Evidence supports simplifying antibiotic regimens for hospital-acquired pneumonia in critically ill patients.